BioSpace News Archive

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the Biologics License Application (BLA) for DAXI in the treatment of moderate to severe glabellar (frown) lines has been accepted for review by the U.S. Food and Drug Administration (FDA)

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has gained two new insurance customers in China for its cancer screening and detection tests (“CDA

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business highlights.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences for the remainder of the quarter.

Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the upcoming presentation of three abstracts at the 16th Annual WORLDSymposium™, taking place February 10-13, 2020, in Orlando, FL.

Express Image Digital announced its interactive Wayfinding Plus platform was selected by a large academic healthcare campus, with 4+ million square feet, in greater Los Angeles area.

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23M.

Intabio, a developer of instrumentation systems for biotherapeutic precision analysis and quality assessment throughout bioproduction, announced a Series B investment of $18 million.

The Alzheimer’s Research and Prevention Foundation announces Dr. Chris Walling as its new Vice President of Education and Outreach.

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that it will release fourth quarter and full year 2019 financial results on Thursday, February 27, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss the financial results and provide a business update.